Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM63O4F)

• Drug Name: PURPUROGALLIN Drug Info
• Synonyms: 3tiy; AC1NQYND; BIDD:ER0545
• Cross-matching ID:
  PubChem CID: 135403797
  ChEBI ID: CHEBI:8647
  CAS Number: CAS 569-77-7
  TTD Drug ID: DM63O4F

Molecule-Related Drug Atlas

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[3]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[4]
Inclacumab	DMXV94M	Sickle-cell disorder	3A51	Phase 3	[5]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[6]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[2]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[7]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[8]
PSI-697	DM75FWO	Atherosclerosis	BD40	Phase 1	[9]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[10]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[11]

Drug(s) Targeting Bcl-x messenger RNA (BCL2L1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TW-37	DMDE8YS	Discovery agent	N.A.	Investigative	[12]
QEDIIRNIARHLAQVGDSMDR	DMJ38YV	Discovery agent	N.A.	Investigative	[13]
4,5-dibenzylbenzene-1,2-diol	DMHURXY	Discovery agent	N.A.	Investigative	[14]
ISIS 11219	DMW3145	Discovery agent	N.A.	Investigative	[15]
ISIS 11220	DMNJS0K	Discovery agent	N.A.	Investigative	[15]
ISIS 11224	DMMGA6K	Discovery agent	N.A.	Investigative	[15]
ISIS 11223	DM7LPI4	Discovery agent	N.A.	Investigative	[15]
ISIS 16010	DMZID0W	Discovery agent	N.A.	Investigative	[15]
ISIS 16009	DMBRKFC	Discovery agent	N.A.	Investigative	[15]
ISIS 15998	DMAQ9EB	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting L-selectin (SELL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[4]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[2]
Hu Dreg 55	DMK1VHF	Psoriasis vulgaris	EA90	Terminated	[16]
2,3,4-trihydroxybenzoic acid	DMWHK35	Discovery agent	N.A.	Investigative	[2]
LD201t1	DMC5XQ6	Inflammation	1A00-CA43.1	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bcl-x messenger RNA (BCL2L1 mRNA)	TTRE6AX	B2CL1_HUMAN	Inhibitor	[1]
L-selectin (SELL)	TT2IYXF	LYAM1_HUMAN	Inhibitor	[2]
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[2]

References

• [1] Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003 Sep 25;46(20):4259-64.
• [2] Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
• [3] Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
• [4] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [5] Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
• [6] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [7] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
• [8] rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
• [9] Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
• [10] WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
• [11] Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
• [12] Fragment-based deconstruction of Bcl-xL inhibitors. J Med Chem. 2010 Mar 25;53(6):2577-88.
• [13] Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
• [14] Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906.
• [15] US patent application no. 7,148,204, Antisense modulation of bcl-x expression.
• [16] Clinical pipeline report, company report or official report of glycomimetics.
• [17] Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.